Equity

The following summarizes the changes in equity for the six months ended June 30, 2017 (dollars in thousands):



	Common stock		Additional paid-in capital		Accumulated earnings less dividends			Accumulated other comprehensive loss			Total equity

Balance at December 31, 2016	$	1,373	$	10,105,654	$	94,899		$	(30,510	)	$	10,171,416
Net income attributable to common stockholders	—		—		401,100			—			401,100
Loss on cash flow hedges, net	—		—		—			(16,013		)	(16,013		)
Cash flow hedge loss reclassified to earnings	—		—		—			3,534			3,534
Change in redemption value of redeemable noncontrolling interest	—		—		(397		)	—			(397		)
Dividends declared to common stockholders	—		—		(391,735		)	—			(391,735		)
Issuance of common stock, net of withholdings	8		100,652		(1,321		)	—			99,339
Amortization of deferred compensation	—		15,168		—			—			15,168
Balance at June 30, 2017	$	1,381	$	10,221,474	$	102,546		$	(42,989	)	$	10,282,412

As of June 30, 2017 and December 31, 2016, the Company's charter authorized a total of 280,000,000 shares of common stock and 50,000,000 shares of preferred stock for issuance.

During the six months ended June 30, 2017, the Company:


i.	issued 36,169 shares of common stock in connection with stock options exercised;


ii.	issued 1,828 common shares through the Company's dividend reinvestment plan;


iii.	issued 201,314 common shares in connection with restricted stock grants and the conversion of performance awards to restricted shares;


iv.	issued 568,424 shares under CEP IV as discussed below;


v.	withheld 59,019 common shares to satisfy employees' tax withholding and other liabilities;


vi.	issued 5,872 common shares through the Employee Stock Purchase Plan; and


vii.	canceled 2,211 common shares of restricted stock upon forfeiture.

Any deferred compensation related to the Company's stock option, restricted stock and performance award grants during the six months ended June 30, 2017 is not reflected on the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017, and will not be reflected until recognized as compensation cost.

In December 2015, the Company commenced a fourth continuous equity program ("CEP IV") under which the Company may sell up to $1,000,000,000 of its common stock from time to time. Actual sales will depend on a variety of factors to be determined by the Company, including market conditions, the trading price of the Company's common stock and determinations by the Company of the appropriate sources of funding for the Company. In conjunction with CEP IV, the Company engaged sales agents who will receive compensation of up to 2.0% of the gross sales price for shares sold. CEP IV also allows the Company to enter into forward sale agreements up to $1,000,000,000 in aggregate sales price of its common stock. The Company expects that, if entered into, it will physically settle each forward sale agreement on one or more dates specified by the Company on or prior to the maturity date of that particular forward sale agreement, in which case the Company will expect to receive aggregate net cash proceeds at settlement equal to the number of shares underlying the particular forward agreement multiplied by the relevant forward sale price. However, the Company may also elect to cash settle or net share settle a forward sale agreement. In connection with each forward sale agreement, the Company will pay the relevant forward seller, in the form of a reduced initial forward sale price, a commission of up to 2.0% of the sales prices of all borrowed shares of common stock sold. As of June 30, 2017, there are no outstanding forward sales agreements. During the three and six months ended June 30, 2017, the Company sold 262,247 and 568,424 shares at an average sales price of $190.66 and $188.39 per share, for net proceeds of $49,250,000 and $105,478,000, respectively. As of June 30, 2017, the Company had $892,915,000 of shares remaining authorized for issuance under this program.